Analytical Data
-
Gene name
Ccl22
- Application
-
Alternative Names
Ccl22；MDC；SCYA22；C-C motif chemokine 22
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00626
-
Expression Region
25-93aa
-
AA Sequence
GPYGANMEDS VCCRDYVRYR LPLRVVKHFY WTSDSCPRPG VVLLTFRDKE ICADPRVPWV KMILNKLSQ
-
Molecular Weight
8.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Ccl22, also known as chemokine (C-C motif) ligand 22, is a member of the CC chemokine family that plays a crucial role in immune responses by facilitating the migration of immune cells, particularly regulatory T cells, to sites of inflammation and tumors. Its expression is tightly regulated and is associated with various pathological conditions, including cancer, autoimmune diseases, and chronic inflammatory disorders. Research into Ccl22 has gained traction due to its potential as a biomarker for disease progression and prognosis, as well as its therapeutic implications in modulating immune responses. Recombinant Ccl22 protein has been developed for various applications, including studying its effects on T cell recruitment and function in vitro and in vivo. Understanding the signaling pathways and mechanisms by which Ccl22 influences immune cell behavior could offer insights into novel treatment strategies for diseases characterized by immune dysregulation. Moreover, the use of Ccl22 in experimental settings could enhance the design of immunotherapies that aim to improve immune system efficacy against tumors while minimizing adverse effects associated with overactive immune responses. As such, the study of recombinant Ccl22 protein not only advances basic immunological research but also holds promise for clinical applications in the realm of immunotherapy and regenerative medicine.
